Brokerages forecast that NewLink Genetics Corp (NASDAQ:NLNK) will post sales of $5.78 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for NewLink Genetics’ earnings, with estimates ranging from $5.00 million to $7.35 million. NewLink Genetics posted sales of $2.76 million during the same quarter last year, which suggests a positive year over year growth rate of 109.4%. The business is scheduled to issue its next earnings report on Thursday, May 3rd.

According to Zacks, analysts expect that NewLink Genetics will report full year sales of $5.78 million for the current year, with estimates ranging from $18.10 million to $20.00 million. For the next year, analysts expect that the company will post sales of $11.37 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow NewLink Genetics.

How to Become a New Pot Stock Millionaire

NewLink Genetics (NASDAQ:NLNK) last released its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.32. The firm had revenue of $10.10 million during the quarter, compared to analysts’ expectations of $2.72 million. NewLink Genetics had a negative return on equity of 60.60% and a negative net margin of 250.60%.

Several equities analysts have weighed in on NLNK shares. Zacks Investment Research upgraded NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 target price on the stock in a report on Wednesday, January 3rd. BidaskClub upgraded NewLink Genetics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Cantor Fitzgerald set a $26.00 target price on NewLink Genetics and gave the company a “buy” rating in a report on Monday, January 8th. Stifel Nicolaus restated a “buy” rating and set a $21.00 target price (down from $25.00) on shares of NewLink Genetics in a report on Friday, March 2nd. Finally, Bank of America cut their target price on NewLink Genetics from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, March 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. NewLink Genetics currently has a consensus rating of “Buy” and a consensus target price of $21.57.

NewLink Genetics (NLNK) traded down $0.12 during midday trading on Wednesday, reaching $7.24. The company’s stock had a trading volume of 966,016 shares, compared to its average volume of 741,713. NewLink Genetics has a one year low of $5.90 and a one year high of $25.17. The company has a market capitalization of $273.47, a price-to-earnings ratio of -3.08 and a beta of 1.25.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of NewLink Genetics by 1,823.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 9,735 shares during the period. Oppenheimer & Co. Inc. bought a new position in shares of NewLink Genetics in the third quarter worth about $114,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of NewLink Genetics in the fourth quarter worth about $118,000. The Manufacturers Life Insurance Company increased its stake in shares of NewLink Genetics by 3.0% in the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 556 shares during the period. Finally, Creative Planning bought a new position in shares of NewLink Genetics in the fourth quarter worth about $152,000. Institutional investors own 65.14% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/5-78-million-in-sales-expected-for-newlink-genetics-corp-nlnk-this-quarter/1940719.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.